Critical Care

INFINIT - Recruiting

Can interferon gamma prevent infection in critically ill patients at highest risk? A phase II randomised controlled trial

• Study stage: Recruiting
• Sponsor: Newcastle upon Tyne Hospitals NHS Foundation Trust
• Funder: Medical Research Council
• Therapeutic area: Critical Care 
• Type of study: CTIMP

Aim: to determine whether IFNg treatment is safe, reduces antibiotic use, reduces infections and best dose

 

Primary outcome:

To determine whether IFNg increases antibiotic-free days, in critically ill patients at high risk of ICU-AI.

• Population: ICU populations
• Clinical Phase: II
• Design: RCT
• Setting: Critical Care
• Planned Sample Size: 282 (including 10% dropout rate)